Single cEll pRofiling PErsistaNce To ImmuNothErapy

Single cEll pRofiling PErsistaNce To ImmuNothErapy is a phase 2, interventional study registered as NCT06680739 by Vall d'Hebron Institute of Oncology, with a registry enrolment figure of 60 participants, started 2022-03-01 and due to reach its primary completion in 2032-07-01. Interventions recorded: Durvalumab; Tremelimumab. Conditions listed: Colorectal Cancer; Endometrial Cancer. Primary outcome: Evaluation of Objective Response Rate (ORR). Colorectal eligibility wording from the registry: ", Health Insurance Portability and Accountability Act in the US, European Union \[EU\] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations". Sites: Spain. No results are recorded here; the registry entry is the source.